DENVER, Colo. (247marketnews.com) -- Bluejay Diagnostics (NASDAQ:BJDX) is laying down a potentially important piece of its commercialization puzzle before its Symphony diagnostic platform can even enter the U.S. market.
The company partnered with Lovell Government Services, a Service-Disabled Veteran-Owned Small Business (SDVOSB), to create a federal distribution and co-marketing framework targeting the VA, Department of Defense, Military Health Systems and Indian Health Service, subject, critically, to FDA clearance or other required regulatory authorization.
Symphony remains investigational and is not yet cleared for commercial diagnostic use in the United States. The partnership is therefore less about near-term revenue than about building the machinery needed to pursue government contracts if and when regulatory approval arrives.
“We believe this partnership represents an important step in building Bluejay’s commercial infrastructure well ahead of potentially marketing medical devices in the US,” CEO Neil Dey said. He added that the companies believe “regulatory, manufacturing and commercial readiness should advance in parallel.”
The potential prize is substantial. The Veterans Health Administration operates roughly 170 major medical centers and 1,193 outpatient clinics, while the broader DoD healthcare system includes approximately 45 military hospitals and 572 clinics, according to the company's announcement. The federal healthcare channel also includes the Indian Health Service.
Lovell brings something Bluejay would otherwise have to build from scratch: established federal procurement infrastructure and SDVOSB status. The company says Lovell can support opportunities involving vehicles including the VA Federal Supply Schedule, GSA Advantage, GSA Multiple Award Schedule, DLA DAPA and ECAT.
That could become particularly relevant if Bluejay's clinical and regulatory strategy succeeds. The company's SYMON-II pivotal study is intended to validate findings from SYMON-I and support a planned 510(k) submission to the FDA. Meanwhile, SYMON-III is evaluating IL-6 in emergency-department patients with increasing infection severity and risk of developing sepsis.
Lovell CEO, Chris Lovell, framed the partnership around the company's federal mission: “Our mission is to connect innovative healthcare technologies with the federal healthcare providers serving our Veterans, active-duty service members, and their families.”
Bluejay is attempting to build the commercial runway before regulatory clearance, rather than waiting until approval to start figuring out how to sell. A rapid IL-6 test capable of producing results in approximately 20 minutes could have meaningful utility in settings where clinicians need timely information for sepsis triage and monitoring.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.